U.S. Pharma Stock News

In February 2026, DNOW Inc. reported fourth‑quarter 2025 sales of US$959 million, up from US$571 million a year earlier, but swung from net income of US$23 million to a net loss of US$147 million as continuing operations moved from earnings per share to losses per share. This shift back into loss‑making territory, despite higher full‑year sales and continued share repurchases, highlights how ERP implementation and integration issues are weighing heavily on profitability and have prompted...

AnaptysBio reported past fourth-quarter 2025 results showing net income of US$49.61 million versus a prior-year net loss, while announcing plans to spin off its biopharma operations into a separate public company, First Tracks Biotherapeutics, targeted for completion in the second quarter of 2026. The combination of sharply improved earnings, reduced full-year net loss to US$13.23 million, and expanding royalty revenue from GSK’s Jemperli underscores how AnaptysBio is reshaping itself around...

Miller Industries (MLR) just wrapped up FY 2025 with fourth quarter revenue of US$171.9 million and basic EPS of US$0.30, alongside net income of US$3.4 million, setting the tone for how the full year is being read by the market. The company has seen quarterly revenue range from US$171.9 million to US$225.7 million over the last four reported quarters, with EPS moving between US$0.27 and US$0.74 as trailing twelve month totals reached US$790.3 million in revenue and EPS of US$2.01. With...

February production snapshot and why it matters CleanSpark (CLSK) released unaudited Bitcoin production figures for February 2026, reporting 568 Bitcoin mined, with peak single day output of 23.84 and an average daily level of 20.29. Because mining volume directly feeds potential revenue, these monthly data points give you a timely read on how CleanSpark's facilities are performing and how consistently they are converting power capacity into Bitcoin. See our latest analysis for...

Globalstar (GSAT) is back in focus after reporting record 2025 revenue and sharply lower net losses, paired with 2026 revenue guidance of US$280 million to US$305 million that signals management confidence. See our latest analysis for Globalstar. At a share price of US$59.41, Globalstar has seen pressure recently with a 13.24% 90 day share price decline and a 7.16% year to date share price pullback. However, the 1 year total shareholder return of 164.99% and 3 year total shareholder return of...

If you are wondering whether NPK International is still attractively priced after its recent run, this article will walk through what the numbers are really saying about the stock. The share price closed at US$13.82, with a 7.2% decline over the last 7 days and a 3.7% decline over the last 30 days, while still showing returns of 14.2% year to date and 145.0% over the past year. These moves are drawing fresh attention to NPK International as investors reassess what the recent performance...

Ferrellgas Partners (OTCPK:FGPR) has just posted Q2 2026 results with revenue of US$641.4 million and basic EPS of US$2.51 on net income of US$102.2 million, putting fresh numbers around its recent return to profitability. Over the last year, the company has seen quarterly revenue range from US$343.6 million to US$669.8 million while basic EPS has swung between a loss of US$33.23 and a profit of US$9.97. This quarter’s profit adds another data point to an already volatile earnings run. For...

Global Water Resources (GWRS) has just closed out FY 2025 with Q4 revenue of US$13.5 million and a basic EPS loss of US$0.03, giving investors a mixed set of headline numbers to digest. The company has seen quarterly revenue range from US$12.5 million to US$15.5 million over the year, while basic EPS has moved between US$0.02 and US$0.06 in the first three quarters before Q4’s loss. With trailing 12 month EPS at US$0.11 on revenue of US$55.8 million and net margin thinner than last year, this...

Match Group (MTCH) has moved to eliminate its Chief Operating Officer role, a decision that will see long serving executive Hesam Hosseini exit on June 2, 2026, raising fresh questions about the company’s future operating priorities. See our latest analysis for Match Group. Match Group's 8.34% 1 month share price return at a last close of US$31.31 comes after a 9.30% decline over 3 months and a 79.25% drop in 5 year total shareholder return. This hints that recent momentum is still fragile...

Macy's (M) has drawn investor attention after recent trading left the stock around $19.19, with short term returns under pressure despite a stronger 1 year total return profile. See our latest analysis for Macy's. Recent trading has pushed Macy's 30 day share price return to a 9.61% decline and its year to date share price return to a 15.65% decline. This comes even though the 1 year total shareholder return of 52.19% signals earlier momentum that now appears to be fading as investors...

Varonis Systems (VRNS) is under pressure after a series of securities class action lawsuits followed third quarter 2025 results that missed expectations, weaker renewals, slower SaaS conversions, lower guidance, and a headcount reduction. See our latest analysis for Varonis Systems. At a latest share price of US$23.83, Varonis has seen short term share price returns of 1.45% over 1 day and 3.20% over 7 days. That sits against a 30 day share price return of 10.18% and a year to date share...

If you are wondering whether Bloom Energy's share price still offers value after a big run, or if you might be late to the story, this article walks through what the current market price could be implying. The stock has seen mixed short term moves, with a 5.1% decline over the last 7 days and a 5.3% decline over the last 30 days, while year to date it is up 62.1% and the 1 year return is very large. Over the past few months, investor attention has focused on Bloom Energy's role in clean...

Par Pacific Holdings (PARR) drew fresh attention after reporting fourth quarter and full year 2025 results along with a new share repurchase program of up to US$250 million, highlighting profitability trends and capital return plans. See our latest analysis for Par Pacific Holdings. The latest earnings and capital return plans come after a powerful run in the shares, with a 7 day share price return of 22.99%, a year to date share price return of 39.50% and a 1 year total shareholder return of...

Keros Therapeutics FY 2025 earnings snapshot Keros Therapeutics (KROS) closed out FY 2025 with Q4 total revenue of US$0.4 million, a basic EPS loss of US$0.86 and net income loss of US$23.5 million, setting a cautious tone after a year that also included a very profitable first quarter. Over the past twelve months, the company has seen total revenue move from US$3.6 million in the TTM period to Q4 2024 to US$244.1 million in the latest TTM period, while basic EPS shifted from a loss of...

Jackson Financial (JXN) just posted Q4 results that topped analyst estimates and led life insurance peers in revenue growth, yet the share price slipped and put the spotlight on investor expectations and mixed analyst reactions. See our latest analysis for Jackson Financial. At a share price of US$111.50, Jackson Financial has given investors a 13.44% 90 day share price return and a 38.69% one year total shareholder return. This suggests momentum has cooled recently after a strong multi year...

Autohome FY 2025 earnings in focus Autohome (NYSE:ATHM) has wrapped up FY 2025 with fourth quarter revenue of about C¥1,462 million and basic EPS of roughly C¥1.94, set against a trailing twelve month EPS of C¥13.40 on revenue of about C¥6,452 million. The company has reported quarterly revenue in a range from C¥1,454 million to C¥1,778 million across FY 2025, with basic EPS between C¥1.94 and C¥3.58, giving investors a clear view of how top line and per share earnings have moved through the...

Catalyst Pharmaceuticals (NasdaqCM:CPRX) reported record full year and Q4 2025 results, highlighting organic growth across its portfolio. The company noted continued market uptake of its lead rare disease treatments, including AGAMREE and FIRDAPSE. Management discussed how recent alliances and product momentum position Catalyst within the rare disease treatment space. Catalyst Pharmaceuticals focuses on therapies for rare neurological and neuromuscular conditions, an area where treatment...

Alto Ingredients (ALTO) closed out FY 2025 with Q4 revenue of US$232 million and basic EPS of US$0.29, alongside net income of US$21.8 million, while on a trailing twelve month basis EPS sat at US$0.18 on revenue of US$917.9 million and net income of US$13.3 million. Over the past four quarters, the company has seen quarterly revenue range between US$218.4 million and US$241.0 million, with EPS swinging from losses of US$0.16 and US$0.15 in Q1 and Q2 2025 to positive readings of US$0.19 and...

Veeva Systems (VEEV) has wrapped up FY 2026 with Q4 revenue of US$836.0 million and basic EPS of US$1.49, backed by trailing twelve month revenue of US$3.2 billion and EPS of US$5.55. The company has seen revenue move from US$699.2 million in Q3 FY 2025 to US$835.9 million in Q4 FY 2026, while quarterly basic EPS stepped up from US$1.15 to US$1.49 over the same stretch, setting up a story that hinges on how consistently those earnings translate into cash and margin resilience. See our full...

Intro paragraph Enhabit (EHAB) just wrapped up FY 2025 with Q4 revenue of US$270.4 million and a basic EPS loss of US$0.76, as the company continued to report negative net income of US$38.7 million for the quarter. Over recent periods, revenue has moved from US$258.2 million in Q4 2024 to US$270.4 million in Q4 2025, while basic EPS shifted from a loss of US$0.92 to a loss of US$0.76. This sets up a results season where investors are watching how consistently the business can translate its...

Invivyd (IVVD) just closed out FY 2025 with fourth quarter revenue of US$17.2 million and a basic EPS loss of US$0.04, alongside net income excluding extra items of a US$11.1 million loss. Over the past few quarters, the company has seen revenue move from US$11.3 million in Q1 2025 to US$13.1 million in Q3 and US$17.2 million in Q4, while quarterly basic EPS moved from a loss of US$0.14 to US$0.06 and then US$0.04. This sets up a results season in which investors are likely to focus on how...

Tesla snapshot and recent returns Tesla (TSLA) is trading around US$405.55, with a 1 day move close to flat, a small gain over the past week, and slight declines over the past month and past 3 months. See our latest analysis for Tesla. That recent softness in the share price comes after a stronger run, with a 1 year total shareholder return of 54.4% and a 3 year total shareholder return of about 1.3x, suggesting momentum has cooled even though long term holders have still seen substantial...

What Amphenol's Recent Returns Tell You Amphenol (APH) has been moving in different directions across timeframes, with a 2.63% gain over the past day contrasted with weaker momentum over the week, month, and past 3 months. For longer term holders, the picture looks different, with the stock showing very large total return over 1 year and multiples of that over 3 and 5 years, which raises questions about how current pricing lines up with fundamentals. See our latest analysis for Amphenol. With...

Arcus Biosciences (NYSE:RCUS) reported new clinical and biomarker data for its CD73 inhibitor casdatifan in late line kidney cancer. The company highlighted strong efficacy signals in renal cell carcinoma and a tight link between biomarker suppression and clinical outcomes. Arcus also outlined first in human plans for an oral MRGPRX2 antagonist and a TNF inhibitor ahead of an upcoming ASCO symposium. For investors watching Arcus Biosciences, the fresh casdatifan data adds a new layer to the...